arXiv:2607. 22143v1 Announce Type: new Abstract: Molecular glue degraders have emerged as a promising strategy for targeted protein degradation by inducing ternary complex formation between an E3 ubiquitin ligase and a target protein.
arXiv:2506. 14488v2 Announce Type: replace-cross Abstract: Structure-based drug design (SBDD) models are central to modern pharmaceutical research, enabling the rational exploration of protein-ligand interactions at atomic resolution.
arXiv:2606. 23856v1 Announce Type: new Abstract: Generative molecular models for drug design are a promising direction with much active research.
arXiv:2606. 11243v1 Announce Type: new Abstract: De novo protein generation has transformative potential in therapeutic design, enzyme engineering, and synthetic biology.
arXiv:2607. 19237v1 Announce Type: new Abstract: Designing small molecule ligands that bind with high affinity to specific protein pockets is a fundamental goal in drug discovery, as small molecules constitute a major fraction of approved therapeutics.
arXiv:2606. 01628v1 Announce Type: cross Abstract: Biomolecules such as proteins and small-molecule ligands play a central role in biological systems, arising from the tight interplay between sequence and three-dimensional structure.
arXiv:2608.21367v1 Announce Type: cross Abstract: Protein-peptide interactions are central to cellular regulation and peptide-based drug discovery, yet existing computational methods mainly focus on...
arXiv:2608.31009v1 Announce Type: new Abstract: Structure-based drug design (SBDD) requires ligands that satisfy both 3D target affinity and 1D chemical validity. Existing controllable generation met...
CODesign is a co-design framework that jointly generates protein sequences and structures to improve consistency between them. It introduces a large consistency‑distilled dataset of about 105,000 dimers and employs a multimodal joint flow model with a consistency‑aware resampling strategy to iteratively refine sequences and side chains. The approach achieves state‑of‑the‑art in silico success rates for protein‑ and ligand‑target binder design, with ablation studies showing a 70.9% performance boost from the distilled dataset and further gains from the resampling mechanism.
FuseDiff is an end‑to‑end diffusion model designed for dual‑target structure‑based drug design, jointly generating a ligand graph and two pocket‑specific binding poses conditioned on both target pockets. It employs a message‑passing backbone with Dual‑target Local Context Fusion (DLCF) to fuse ligand atom contexts from both pockets, preserving symmetry while enabling expressive joint modeling. The model enforces topological consistency across the two poses and allows target‑specific geometric adaptation, achieving state‑of‑the‑art docking performance and enabling systematic assessment of dual‑target pose quality before docking‑based pose search.
arXiv:2606. 06717v1 Announce Type: cross Abstract: While generative AI models have demonstrated remarkable success in structure-based drug design, they predominantly rely on deep binding pockets and struggle to sample effective ligands for challenging low-pocketability targets, such as the historically "undruggable" oncology targets KRAS and MYC.
arXiv:2608. 16094v1 Announce Type: new Abstract: Accurate protein structure prediction is fundamental to structural biology because protein structure underlies molecular function and provides a basis for mechanistic interpretation.
The paper proposes a new framework called ensemble-conditioned guidance that reframes molecular design as an optimisation over both the modes and properties of a molecule’s conformational ensemble. It allows 3D generative models to be conditioned simultaneously on multiple axes—such as shapes, pharmacophore profiles, or protein pockets—by adaptively combining vector fields from each condition. The authors introduce adaptive symmetry learning for composable conditions across reference frames, extend the framework to support flexible-size generation, and demonstrate its effectiveness on new benchmarks and practical drug‑discovery tasks, showing improved outcomes when conditioning on additional states compared to single‑state approaches.